FDA Panel Recommends Approval of Promising Alzheimer's Drug Donanemab

Eli Lilly's new treatment shows potential in slowing cognitive decline but raises safety and accessibility concerns.

The FDA advisory committee voted unanimously in favor of donanemab, citing its effectiveness in early-stage Alzheimer's.
Donanemab targets amyloid plaques in the brain, slowing disease progression by 22% in early-stage patients.
Key safety concerns include brain inflammation and bleeding, particularly in genetically predisposed individuals.
The panel highlighted the need for more research on the drug's effects in underrepresented racial and ethnic groups.
Final FDA approval is pending, with potential implications for broader Alzheimer's treatment strategies.